Lymphoma NGS Ig/TCR clonal rearrangement test

The 2020 version of the CSCO lymphoma diagnosis and treatment guidelines states that Ig/TCR clonal rearrangement testing can assist in: ① lesions that are difficult to distinguish between benign and malignant; ② Suspected lymphoma; ③ Diagnosis and differentiation of certain specific diseases; ④ Tumors with complex cell composition or difficult to distinguish cell lines with immune markers; ⑤ Tumor cloning correlation analysis; ⑥ Assessment of minimal residual lesions.

1. the significance of T/B lymphocytes by weight ranking detection for the diagnosis and treatment of lymphoma

T/B lymphocytes undergo receptor gene rearrangement when they mature, which plays an important role in the diagnosis and treatment of lymphoma. The 2020 edition of the CSCO lymphoma guidelines indicate that Ig/TCR clonal rearrangement testing can assist with: 

(1) Benign and malignant lesions that are difficult to distinguish;

(2) suspected lymphoma;

(3) Diagnosis and identification of certain specific diseases;

(4) tumors with complex cell composition or difficult to distinguish cell lines with immune markers;

(5) Tumor cloning correlation analysis;

(6) Evaluation of minimal residual lesions.

NCCN B-cell lymphoma 2020 version 1 states that when lymph nodes are not easily resected or incisional biopsy, core needle biopsy is combined with appropriate ancillary techniques (molecular analysis of immunoglobulin heavy chain variables [IGHV]). and T cell receptor [TCR] gene rearrangement) for differential diagnosis.


2. Pan-cause medicalNGS Ig/TCRclonal rearrangement detection products

(1)Product composition

The detection range includes IGH VDJ and DJ, IGKL VJ and TRB VDJ and DJ, TRG VJ, and at the same time add quality control products for quality control.

(2)Product principle

By IGH VDJ and DJ, IGKL VJ primer combination or TRB VDJ and DJ, TRG VJ primer combinations are multiplex PCR amplification sequencing to analyze for clonal rearrangements and V-region hypermutation rates can be analyzed.

(3)Product advantages


  • Accurate to the cloning sequence and frequency, can track and monitor, reduce false positive and false negative. The CE method cannot distinguish clones of the same length and different sequences, which will be misjudged as oligoclones and cause false positives; The peaks inside and outside the range cannot be distinguished whether they are the same clone, which will be misjudged as multiple clonals and cause false negatives; In the context of polyclonal with low tumor burden, the peak value of tumor clones will be relatively low, and it is difficult to judge whether there is monoclonal proliferation by CE method.

  • Accurate and sensitive experimental system, while expanding the receptor chain to improve the detection rate of tumor cells. 

The system is based on accurate and unbiased Ig/TCR multiplex PCR for rearrangement detection. B lymphocytes are tested by weight ranking, including IGH, IGK, IGL, and T lymphocytes are tested by weight ranking TRB and TRG.


  •  Easy and fast operation. The whole process can be automated, and only 2 reaction tubes are required for T/B simultaneous detection, one tube amplifying Ig and one tube amplifying TCR. One-time experiments can analyze both rearranged clones and V-region mutations.

  • It can be used for subsequent sample MRD detection with high sensitivity10-6to predict recurrence and survival. Establish an unbiased amplification system without being affected by tumor cell surface antigen drift and clonal evolution.

 

(4)Method comparison 


Electrophoresis (GEL/CE method).

Sequencing capillary electrophoresis

NGS clonal rearrangement assay

Detection principle

The main band in the size range of Ig and TCR fragments was used to identify whether clonal hyperplasia was identified

The main band in the size range of Ig and TCR fragments was used to identify whether clonal hyperplasia was identified

Ig and TCR sequencing data were used to identify clonal hyperplasia with clonal sequence and frequency

V-region mutation detection

No, no sequence is obtained

Yes, the purity of the product is required to be high, otherwise it is necessary to cut the rubber or TA clone first

Yes, get the information you need right the time

Simultaneous detection of 2 or more tumor clones

not

Yes, pick and choose to sequence clones

Yes, you can get clones and frequencies

Detect multiple chains simultaneously

No, sequencing is not possible

No, mixing sequencing is not possible

Yes, mix a lane/run on the machine



3.Clinical application scenarios

It covers the whole course of lymphoma diagnosis and treatment, and assists the precise diagnosis and treatment of lymphoma.

        (1) Assist in the identification of benign and malignant lymphoma and suspected lymphoma (monoclonal/polyclonal);

        (2) Helps identify the types of lymphoma (B-cell lymphoma/T-cell lymphoma);

        (3)Assist in identifying lymphoma maturity (V-zone mutation rate) according to the rearranged form;

        (4)Auxiliary selection of treatment methods (degree of histological transformation of indolent lymphoma);

        (5) Prognosis judgment, whether there is a mutation in the IGHV gene in the international prognostic index of chronic lymphocytic leukemia is one of the indicators (IGHV mutation ratio2% had a good prognosis and <2% had a poor prognosis)

        (6) Assist in the identification of histological transformation of indolent lymphoma (analysis of tumor cloning correlation)


4. Sample delivery requirements 

Sample type

Sample characteristics

Sample specifications

Shipping requirements

Paraffin tissue sections

Paraffin sectioning

Thickness 5-8μm, 5-10 sheets

room temperature

Fresh tissue

Site of the lesion

>1cm3

Dry ice after cryopreservation

marrow

Fresh bone marrow fluid (with evidence of infiltration)

>2ml

       

EDTA anticoagulation tube cryogenic

Peripheral blood

Fresh or frozen peripheral blood

>2ml

Fresh low temperature or dry ice after freeze

DNA

Concentration> 25ng/ul

Before treatment> 0.5 μg

microtherm

 

5. Product process

The testing cycle is 14 calendar days.



图片关键词

Contact Us

8/F, Block A, Hengtemei Building, No. 3 Ganli Road, Longgang District, Shenzhen; 402, Kelente R&D Building, Ganli Road, Longgang District, Shenzhen.

TEL: 0755-8453-4802

EMAIL

query@neoimmune.cn